Develops antibody-based immunotherapies for cancer and infectious disease for patients, alongside vaccine adjuvants for vaccine developers.
10-K for FY2025, filed Mar 16, 2026
Patients receive BOT+BAL through authorized access programs at hospitals and through physicians; pharmaceutical companies work with Agenus through collaboration and licensing agreements for antibody programs.
10-K for FY2025, filed Mar 16, 2026During the year ended December 31, 2025, we began recognizing pre-commercial product revenue for BOT+BAL provided to patients through…View ↗
Revenue is recognized as the gross amount invoiced to the customer net of reserves for estimated variable consideration (for AAC patients)…View ↗
We have entered into collaborations with several companies, including Bristol-Myers Squibb Company (“BMS”), Betta Pharmaceuticals Co., Ltd.…View ↗
10-K for FY2025, filed Mar 16, 2026
For the years ended December 31, 2025, 2024 and 2023, 95%, 98% and 73%, respectively, of our revenue was earned from one collaboration…View ↗
Yes. It kept less than a cent of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$77.2M.
10-K for FY2025, filed Mar 16, 2026
−$20.2MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
A narrower development focus
The older report described a broad pipeline of antibodies, cell therapies and vaccine adjuvants, supported by in-house manufacturing. The latest report prioritizes BOT/BAL and says some other preclinical and clinical work is paused while Agenus evaluates partners.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 16, 2026We are a clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections…View ↗
Manufacturing moved toward collaborations
The older report highlighted in-house cGMP manufacturing; the latest says Agenus sold its Emeryville and Berkeley biologics facilities to Zydus and will maintain manufacturing flexibility through collaborations.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 16, 2026We are a clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections…View ↗
Competes with Bristol Myers Squibb, Merck &, Regeneron Pharmaceuticals, Roche / Genentech, AstraZeneca, Merck KGaA, GSK, Coherus BioSciences, Incyte, BeiGene, Checkpoint Therapeutics, Akeso Biopharma, CStone Pharmaceuticals, Harbour BioMed, Innovent Biologics, AbbVie, Amgen, Novartis, Pfizer, and Sanofi
10-K for FY2025, filed Mar 16, 2026Bristol Myers Squibb markets Ipilimumab (anti-CTLA-4), Nivolumab (anti-PD-1), and Relatlimab (anti-LAG-3), and is developing agents…View ↗
Loading...